Raymond James Financial Inc. Takes $3.63 Million Position in Certara, Inc. (NASDAQ:CERT)

Raymond James Financial Inc. bought a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 340,649 shares of the company's stock, valued at approximately $3,628,000. Raymond James Financial Inc. owned approximately 0.21% of Certara at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Wasatch Advisors LP boosted its stake in Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company's stock worth $105,577,000 after purchasing an additional 1,651,076 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Certara by 169.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock valued at $21,248,000 after acquiring an additional 1,253,385 shares during the period. Glenmede Trust Co. NA grew its stake in Certara by 78.6% during the third quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company's stock valued at $14,123,000 after acquiring an additional 530,598 shares in the last quarter. Kopion Asset Management LLC grew its stake in Certara by 46.0% during the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock valued at $5,918,000 after acquiring an additional 175,005 shares in the last quarter. Finally, Edgestream Partners L.P. bought a new stake in Certara during the 3rd quarter worth approximately $1,782,000. 73.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on CERT shares. TD Cowen initiated coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price target for the company. Barclays upped their target price on Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. Stephens reiterated an "overweight" rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Finally, William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Certara presently has a consensus rating of "Moderate Buy" and an average price target of $15.83.

Remove Ads

Certara Price Performance

CERT traded down $0.01 during midday trading on Monday, hitting $9.90. The stock had a trading volume of 1,579,830 shares, compared to its average volume of 1,038,416. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.18. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The business has a fifty day moving average of $12.40 and a 200 day moving average of $11.44. The company has a market cap of $1.59 billion, a P/E ratio of -49.50, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.